Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00061828
Other study ID # PROBE Study - ChiLDReN Network
Secondary ID U01DK103149U01DK
Status Recruiting
Phase
First received
Last updated
Start date April 21, 2004
Est. completion date May 2029

Study information

Verified date June 2024
Source Arbor Research Collaborative for Health
Contact Terese A Howell
Phone 734 476-5340
Email terri.howell@arborresearch.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Biliary atresia, idiopathic neonatal hepatitis, and specific genetic cholestatic conditions are the most common causes of jaundice and hyperbilirubinemia that continue beyond the newborn period. The long term goal of the Childhood Liver Disease Research Network (ChiLDReN) is to establish a database of clinical information and plasma, serum, and tissue samples from cholestatic children to facilitate research and to perform clinical, epidemiological and therapeutic trials in these important pediatric liver diseases.


Description:

This is a multi-center project to establish a prospective database of clinical information and a repository of blood, and tissue samples from children with diagnoses of neonatal liver diseases, such as biliary atresia (BA), idiopathic neonatal hepatitis (INH), and specific neonatal presentations of genetic cholestatic disorders in order to perform research in these important liver problems. Children will be screened and enrolled at presentation at the participating pediatric liver sites. Participants diagnosed with BA will be followed intensively for the first year, at 18 months of age, and then annually up to 20 years of age, or liver transplantation. Other participants diagnosed with cholestasis will be followed on the same schedule; if there is complete (clinical and biochemical) resolution of their underlying liver disease off all therapy, there will be one follow up visit within one year (preferably scheduled at the time of the next planned follow up visit or at 12 months of age, whichever is later) for data collection and to obtain blood samples. The development of a serum and tissue bank of specimens from children with various neonatal cholestatic disorders will be an invaluable tool for current and future investigations into the etiology and pathogenesis of hepatobiliary injury in the infant. Detailed clinical data, laboratory investigations, liver and biliary specimens, and long-term follow-up of outcomes are part of the normal standard of care with respect to the diagnosis and treatment of the subjects with liver problems. This research involves the collection of diagnostic, clinical and outcome data concerning the subject, which is kept without identification (coded) in a national research database of infants with liver disease. Samples of blood will be obtained for later research analysis, whenever possible, at the time of clinically indicated blood draws or when there is IV access for a clinical procedure. When liver biopsy specimens are obtained for diagnostic purposes, any liver biopsy specimen in excess of that needed for diagnostic use will be sent to the tissue repository. When a portoenterostomy or liver transplant occurs, sections of the liver and, biliary remnant removed in the course of surgery and in excess of that needed for diagnostic use, will be sent for the repository. These specimens will be used in investigations into the mechanisms and causes of the liver damage that occur in the participant's condition. . All data from this study will be kept in a secure research database at the Scientific Data Coordinating Center (SDCC) and transferred to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) data repository after the study ends.


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date May 2029
Est. primary completion date May 2029
Accepts healthy volunteers No
Gender All
Age group N/A to 6 Months
Eligibility INCLUSION CRITERIA - Infant's age less than or equal to 180 days at initial presentation at the ChiLDREN clinical site. - Diagnosis of cholestasis defined by serum direct or conjugated bilirubin greater than 20% of total and greater than or equal to 2 mg/dl. - The subject's parent(s)/guardian(s) willing to provide informed written consent. EXCLUSION CRITERIA - Acute liver failure. - Previous hepatobiliary surgery with dissection or excision of biliary tissue. - Diagnoses of bacterial or fungal sepsis (except where associated with metabolic liver disease) - Diagnoses of hypoxia, shock or ischemic hepatopathy within the past two weeks (If the cholestasis persists beyond two weeks of the initiating event, the infant can be enrolled). - Diagnosis of any malignancy. - Presence of any primary hemolytic disease (except when diagnosed with biliary atresia or another cholestatic disease being studied by ChiLDREN). - Diagnosis of any drug or Total parenteral nutrition (TPN)-associated cholestasis (except when diagnosed with biliary atresia or another cholestatic disease being studied by ChiLDREN). - Diagnosis with Extracorporeal membrane oxygenation (ECMO)-associated cholestasis. - Birth weight less than 1500g (except when diagnosed with biliary atresia).

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Canada The Hospital for Sick Children Toronto Ontario
United States Children's Healthcare of Atlanta - Emory University Atlanta Georgia
United States Children's Hospital Colorado Aurora Colorado
United States Johns Hopkins School of Medicine Baltimore Maryland
United States Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio
United States Baylor College of Medicine Houston Texas
United States Riley Hospital for Children Indianapolis Indiana
United States Children's Hospital Los Angeles Los Angeles California
United States Mount Sinai Medical Center New York New York
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania
United States UPMC Children's Hospital of Pittsburgh Pittsburgh Pennsylvania
United States Washington University School of Medicine Saint Louis Missouri
United States University of Utah Salt Lake City Utah
United States University of California San Francisco California
United States Seattle Children's Hospital Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
Arbor Research Collaborative for Health National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in disease severity over time (disease progression) disease progression defined by transplant date, date of death, worsening liver function, and complications related to worsening liver function Measured at baseline, 1month, 2 months, 3, 6 months post-baseline, 12 and 18 months of age, then annually through year 15.
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT03667534 - Dry Blood Spot Screening Test for Neonatal Cholestasis Patients
Completed NCT02652533 - Ultrasound Shear Wave Elastography Evaluation of Suspected and Known Biliary Atresia
Completed NCT01443572 - The Comparison of Desflurane and Sevoflurane on Postoperative Recovery and Hepatic Function of Biliary Atresia Patients During Kasai Operation N/A
Recruiting NCT04373941 - Part II: Granulocyte-Colony Stimulating Factor Adjunct Therapy for Biliary Atresia Phase 2
Completed NCT01854827 - Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia Phase 1/Phase 2
Completed NCT00007033 - Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease N/A
Recruiting NCT05848310 - Preoperative Serum FGF19 in the Prognosis of Biliary Atresia
Recruiting NCT05072626 - High Medium-chain Triglyceride Nutritional Support in Infants With Biliary Atresia
Completed NCT02292862 - Maternal Microchimerism in Lymph Nodes of Infants With Biliary Atresia at Time of Kasai's Operation N/A
Completed NCT00294684 - A Randomized, Double-Blinded, Placebo-Controlled Trial of Corticosteroid Therapy Following Portoenterostomy N/A
Active, not recruiting NCT02922751 - FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)
Recruiting NCT06184971 - Biliary Atresia Research Network Northeast
Recruiting NCT04260503 - Gut Microbiome in Biliary Atresia
Not yet recruiting NCT06260566 - Tolerability of Enteral NAC in Infants Phase 1
Completed NCT01322386 - Gastrointestinal Microbiota in Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin Phase 1
Recruiting NCT05909033 - Early Predictors for the Short Term Native Liver Survival in Patients With Biliary Atresia After Kasai Procedure
Completed NCT03499249 - N-Acetylcysteine in Biliary Atresia After Kasai Portoenterostomy Phase 2
Recruiting NCT00345553 - Biliary Atresia Study in Infants and Children
Recruiting NCT05521152 - Norepinephrine for Prevention of Intraoperative Hypotension in Infants Undergoing Kasai Portoenterostomy Phase 3
Not yet recruiting NCT05783518 - Effect of Desflurane on Pediatric Acute Respiratory Distress Syndrome After Living Donor Liver Transplant Recipients Phase 4